Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.54 |
| ▸ | CA9 | Q16790 | 4/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2761879 | 0.79 | MET (0.56) | CA12CA9CA1METNPSR1 | |
| SCHEMBL3587194 | 0.76 | CA12 (0.50) | CA12CA9CA1METCSNK2A2 | |
| SCHEMBL10793740 | 0.76 | MAOA (0.49) | CA12CA9CA1METNPSR1 | |
| SCHEMBL2761855 | 0.75 | KMT2A (0.66) | CA12CA9CA1METLMNA | |
| SCHEMBL3087727 | 0.74 | MET (0.49) | CA12CA9CA1METCSNK2A2 | |
| SCHEMBL3585887 | 0.73 | MET (0.53) | CA12CA9CA1METLMNA | |
| SCHEMBL28480556 | 0.73 | MET (0.61) | CA12CA9CA1METLMNA | |
| SCHEMBL30693881 | 0.73 | MET (0.61) | CA12CA9CA1METLMNA | |
| SCHEMBL3575287 | 0.72 | MET (0.56) | CA12CA9CA1METLMNA | |
| SCHEMBL5084867 | 0.71 | PIM1 (0.51) | CA12CA9CA1METLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795299-B2 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090118356-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| EP-1722779-A4 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | UNIV NORTH CAROLINA (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7495026-B2 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1722779-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | The University of North Carolina at Chapel Hill (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050250751-A1 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005087225-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118356-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | BRCA1, CYP19A1, HUNK | CA12 3619/4885CA9 2986/4885CA1 4290/4885 |
| US-20050250751-A1 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | BRCA1, CYP19A1, CYP51A1 | CA12 3791/4885CA9 3248/4885CA1 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.